A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia
Latest Information Update: 12 Mar 2024
Price :
$35 *
At a glance
- Drugs Anti CD19 Chimeric Antigen Receptor T cell therapy Takara Bio (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mesna (Primary)
- Indications Lymphoid leukaemia
- Focus Adverse reactions
- 31 Jan 2024 Planned End Date changed from 1 Jan 2026 to 1 Jun 2027.
- 31 Jan 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jun 2026.
- 27 Nov 2023 Planned initiation date changed from 1 Oct 2023 to 1 Dec 2023.